Institut de Cancérologie des Hauts-de-France

What Institut de Cancérologie des Hauts-de-France does

The Institut de Cancérologie des Hauts-de-France (ICHF) is a physician-led Société Civile Professionnelle operating two cancer treatment centers in the Hauts-de-France region of France: Centre Marie Curie in Arras (founded 1971, relocated to Parc des Bonnettes in January 2011) and Centre Pierre Curie in Beuvry, near Béthune (built 2001). The institute employs 10 oncologist-physicians and approximately 60 staff members who collectively deliver diagnosis, treatment, and post-treatment surveillance for solid tumors including breast, prostate, lung, ORL, digestive, urological, and gynecological cancers.

ICHF's service portfolio spans radiotherapy, chemotherapy, immunotherapy, hormonotherapy, and stereotactic radiotherapy, supported by an advanced equipment stack that includes VisionRT (positioning/monitoring), Elekta linear accelerators, Pinnacle treatment planning, and Therapanacea technology. Treatment decisions are made collectively through Réunions de Concertation Pluridisciplinaire (RCP) involving at least three specialists per case. Revenue is generated through reimbursement via the French Sécurité Sociale and complementary health insurance (mutuelle), with chemotherapy services physically delivered through partnerships with Hôpital Privé Arras les Bonnettes, Clinique Anne D'Artois, and Clinique Ambroise Paré. Patients also access a digital portal (Mon Portail Patient) for care coordination.

The institute operates within a tightly coordinated regional oncology ecosystem, including membership in the 3C Arrageois and 3C Béthunois cancer coordination networks (established 2010), Onco-Artois, and Réseau de Cancérologie du Bôthunois (2006-2007), with referral flows anchored to French national cancer policy (Plan Cancer). The entity has no external parent or private equity backing and maintains a stated share capital of €7,500.

Name

Institut de Cancérologie des Hauts-de-France

Legal name

Institut de Cancérologie des Hauts-de-France

Website

https://ichf.fr

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

11–50 employees

Short description

The Institut de Cancérologie des Hauts-de-France is a physician-led oncology practice operating two cancer treatment centers in Arras and Beuvry, delivering radiotherapy, chemotherapy, immunotherapy, and hormonotherapy to cancer patients in the Hauts-de-France region through the French social security system.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Radiation Oncology (HLAKAFAC), Medical Oncology (HLAKAFAB), Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

• Radiation oncology services
• Cancer treatment center
• Radiotherapy treatment
• Chemotherapy administration
• Multidisciplinary oncology care

Headquarters

HQ city

Arras

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Treatment Services: Revenue generated from cancer treatment services including radiotherapy, chemotherapy, immunotherapy, and hormonotherapy, reimbursed through the French social security system and complementary health insurance

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

The Institut de Cancérologie des Hauts-de-France (ICHF) operates two cancer treatment centers — Centre Marie Curie in Arras and Centre Pierre Curie in Beuvry — providing radiotherapy (including stereotactic radiotherapy), chemotherapy, immunotherapy, and hormonotherapy to cancer patients in the Hauts-de-France region. Treatment plans are defined collectively during weekly multidisciplinary Réunions de Concertation Pluridisciplinaire (RCP), and patients receive follow-up surveillance for up to 5 years post-treatment.

Product overview

The Institut de Cancérologie des Hauts-de-France is a professional civil partnership (Société Civile Professionnelle) operating two cancer treatment centers: Centre Marie Curie in Arras and Centre Pierre Curie in Beuvry. The institute employs 10 oncologists supported by approximately 60 staff members. Services include radiotherapy (including stereotactic radiotherapy), chemotherapy, immunotherapy, and hormonotherapy. Treatment decisions are made through multidisciplinary tumor board meetings (RCP). The institute also provides a patient portal (Mon Portail Patient) for care coordination.

Differentiator

Problem solved

Functional benefit

Brands

• Centre Marie Curie: Cancer treatment center located in Arras, founded in 1971, offering radiotherapy and other cancer treatments.
• Centre Pierre Curie

Products and services

• Centre Marie Curie (Arras cancer treatment center) Cancer treatment center in Arras providing radiotherapy and oncology services for breast, gynecological, digestive, lung, ORL, prostate, urological and other solid tumors. Operated by the ICHF oncologists.
• Centre Pierre Curie (Beuvry cancer treatment center) Cancer treatment center in Beuvry (near Béthune) providing radiotherapy and oncology services including urological and prostate cancer treatments. Operated by the ICHF oncologists.
• Radiotherapy (Radiothérapie) Use of radiation to destroy cancer cells by blocking their ability to multiply, delivered in curative, palliative, and urgent modalities. Approximately two-thirds of cancer patients receive radiotherapy at some stage of care.
• Chemotherapy (Chimiothérapie) Drug-based treatment that destroys cancer cells or prevents their multiplication; administered intravenously, in day hospitalization, or at home. Partner hospitals include Hôpital privé Arras les Bonnettes, Clinique Anne D'Artois, and Clinique Ambroise Paré.
• Immunotherapy (Immunothérapie) Treatment that uses the body's immune system to eliminate cancer cells, administered via intravenous infusion every 2, 3, or 4 weeks with sessions lasting 30 minutes to 1 hour.
• Hormonotherapy (Hormonothérapie) Medication-based treatment that blocks hormone production or opposes hormone action to reduce cancer cell growth; used when the cancer has positive hormone receptors.
• Stereotactic Radiotherapy (Stéréotaxie) Specialized radiotherapy technique enabling precise targeting of tumors with high radiation doses and sub-millimeter accuracy, leveraging VisionRT positioning technology.
• Réunion de Concertation Pluridisciplinaire (RCP) — Multidisciplinary Tumor Board Weekly multidisciplinary meetings where patient cases are reviewed by at least three specialists (surgeon, radiotherapist, oncologist, radiologist) to determine optimal treatment strategies based on latest scientific studies.
• Mon Portail Patient (Patient Portal) Online patient portal providing patients with access to personal health information and care coordination tools throughout their treatment journey.

Quantifiable outcome

• Approximately 2/3 of cancer patients are treated by radiotherapy at some stage of their care
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Réseau de Cancérologie du BéthunoiscoreStrategic or Co-development Partner · 27 March 2007Regional cancer network established in March 2007. Coordinates multidisciplinary RCP meetings for urology, gynecology and senology cancers in the Béthunois territory.
• Onco-ArtoiscoreStrategic or Co-development Partner · 22 December 2006Regional cancer network established in December 2006 by Centre Hospitalier d'Arras, Clinique Bon Secours, and Centre de radiothérapie Marie Curie. Coordinates multidisciplinary RCP meetings for pneumology, gastroenterology, gynecology, senology, dermatology, and ORL cancers.
• 3C ArrageoiscoreStrategic or Co-development PartnerCentre de Coordination en Cancérologie for Arrageois territory, created December 2010, including Centre Hospitalier d'Arras and Hôpital Privé Arras les Bonnettes. Ensures quality, coordination and continuity of cancer care.
• 3C BéthunoiscoreStrategic or Co-development PartnerCentre de Coordination en Cancérologie for Béthunois territory, created November 2010, including Centre Hospitalier de Béthune, Clinique Ambroise Paré, Polyclinique Anne d'Artois, Clinique Médico-chirurgicale de Bruay, and Polyclinique de la Clarence de Divion.
• AIRE Cancers BéthuneminorStrategic or Co-development PartnerCancer patient welcoming, information and support space located at Centre Hospitalier de Béthune, in partnership with Groupement Hospitalier Privé de l'Artois, Clinique Ambroise Paré, and Centre Pierre Curie.
• Espaces Ressources CancersminorStrategic or Co-development PartnerFree resources spaces dedicated to the well-being of people facing cancer, located near their homes.
• PREVARTminorStrategic or Co-development PartnerHealth prevention association in Artois region, 42-48 avenue de la ferme du Roy, 62400 BETHUNE. Partner for cancer prevention and health maintenance.
• Institut National du CancercoreStrategic or Co-development PartnerFrench national cancer agency providing expertise and scientific guidance in oncology. Located at 52 avenue André Morizet, 92513 Boulogne Billancourt.
• ONCO Hauts-de-FrancecoreStrategic or Co-development PartnerRegional cancer network for Hauts-de-France region, located at 14 Rue Jean Walter, 59000 Lille.
• Maison NénupharminorStrategic or Co-development PartnerPersonalized spaces to support patients and families through cancer illness from diagnosis through recovery. Located at 15 rue Willy Brandt.
• Hôpital privé Arras les BonnettescoreChannel Partner/ Reseller/ DistributorPrivate hospital partner for inpatient and day hospitalization chemotherapy administration services.
• Clinique Anne D'ArtoiscoreChannel Partner/ Reseller/ DistributorPartner clinic for outpatient chemotherapy administration services.
• Clinique Ambroise ParécoreChannel Partner/ Reseller/ DistributorPartner clinic for outpatient chemotherapy administration services.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Gustave Roussy: Leading European cancer center in Villejuif/Paris offering radiotherapy, chemotherapy, immunotherapy, and clinical research. ICHF physicians trained there; represents the top-tier national benchmark.
• Institut Curie: Major Parisian oncology hospital and research center (CLCC) treating all cancer types. Several ICHF founders trained there; broader incumbent that anchors the national radiotherapy/oncology reference network.

Direct peers

• Institut Bergonié: Unicancer CLCC in Bordeaux covering all oncology specialties with research programs. Comparable French regional specialist cancer center with similar care model.
• Centre Oscar Lambret: Unicancer Comprehensive Cancer Center located in Lille within the same Hauts-de-France region as ICHF. Provides multidisciplinary oncology care including radiotherapy, chemotherapy, and surgery with research programs — the most direct regional comparable.
• Centre Léon Bérard: Unicancer CLCC in Lyon offering comprehensive multidisciplinary oncology including radiotherapy and clinical research. Comparable French specialist cancer center of similar clinical scope.
• Institut de Cancérologie Jean Godinot: Unicancer CLCC in Reims, northeastern France, offering multidisciplinary oncology treatment and research. Comparable as a regional reference oncology center; ICHF physician Aurélie Fadin trained there.
• Institut Paoli-Calmettes: Unicancer CLCC in Marseille providing radiotherapy, chemotherapy, and surgical oncology. Comparable French regional Comprehensive Cancer Center with multidisciplinary care model.
• Centre François Baclesse: Unicancer CLCC in Caen (Normandy) offering comprehensive radiotherapy, chemotherapy, and oncology surgery. Directly comparable French regional cancer center with similar multidisciplinary model.

Others

• Elekta: Swedish-headquartered vendor of linear accelerators and radiation therapy equipment used by ICHF. Relevant ecosystem participant as a technology supplier shaping ICHF's clinical capabilities.
• Unicancer: Federation of French CLCCs coordinating 18 cancer centers including shared purchasing, research, and quality programs. Relevant as the network governing ICHF's regional peers and a potential counterparty for partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/institut-de-canc%C3%A9rologie-des-hauts-de-france

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut de Cancérologie des Hauts-de-France